Feature Channels: Clinical Trials

Filters close
Released: 1-Jul-2022 12:15 PM EDT
COVID-19 Vaccine Protects People of All Body Weights From Hospitalization and Death, Study of 9 Million Adults in England Suggests
Lancet

COVID-19 vaccines greatly reduced the number of cases of severe COVID-19 disease for everyone regardless of their body size, according to a new study published in The Lancet Diabetes & Endocrinology. Vaccine effectiveness was similar for those with a higher BMI and of a healthy weight, but slightly lower in the underweight group, who were also the least likely to have been vaccinated.

Released: 30-Jun-2022 12:05 PM EDT
Joseph M. Sanzari Children’s Hospital Offers New Clinical Trial for Children and Young Adults Diagnosed with Aggressive or Recurrent Brain Tumor
Hackensack Meridian Health

Joseph M. Sanzari Children’s Hospital at Hackensack University Medical Center — a member of the global Pacific Pediatric Neuro-Oncology Consortium (PNOC) research group — is participating in a PNOC clinical trial for children and young adults with recurrent or progressive high-grade glioma (HGG), an aggressive, fast-growing type of brain tumor. The hospital is one of only 12 centers in the U.S., and the only center in the New York metropolitan area, to offer this trial.

Released: 27-Jun-2022 3:00 PM EDT
Treatment with Cell Cycle Inhibitors: Another Caveat on a Clinical Trial for Mesothelioma Red-Flagged in Lancet Oncology
Sbarro Health Research Organization (SHRO)

There is a growing awareness that the design of clinical trials can be misleading and provide evidence that does not end up actually benefiting patients in the clinical setting.

Newswise: Karallief Announces Granted Patent for Easy Climb Fast Acting Formula Clinically Shown to Improve Joint Comfort
Released: 27-Jun-2022 9:00 AM EDT
Karallief Announces Granted Patent for Easy Climb Fast Acting Formula Clinically Shown to Improve Joint Comfort
Karallief

Karallief® Inc., a leading nutraceutical ingredient company that researches, develops, and distributes clinically studied herbal extract ingredient formulas, announced today that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 11,364,255 for Karallief® Easy Climb®.

Newswise: Henry Ford Health Participated in Novel Clinical Trial Without In-Person Patient Involvement
Released: 23-Jun-2022 11:10 AM EDT
Henry Ford Health Participated in Novel Clinical Trial Without In-Person Patient Involvement
Henry Ford Health

DETROIT (June 22, 2022) –Henry Ford Health was part of a multi-institutional heart failure study that was launched and executed completely virtual during the COVID-19 pandemic. The novel study design could serve as a model for future research.Unlike traditional clinical trials that involve in-person clinic visits, researchers in this study engaged directly with more than 400 patients through a mobile app and secure website to collect participants’ data and other information.

Released: 23-Jun-2022 6:00 AM EDT
Scientists Hope to Create a Health ‘Scorecard’ for Dementia Risk
UC Davis Health

An important new study of diverse communities is looking at how brain changes, genetics and other factors contribute to dementia and Alzheimer’s disease. The results could affect millions. Among people 65 and older, about 1 in 9 has Alzheimer’s disease.

20-Jun-2022 4:05 PM EDT
Listeria-based Booster Skyrockets Vaccine’s Protection Against Recurring Colon Cancer
Thomas Jefferson University

New research in mice from Thomas Jefferson University has paved the way for a Phase I clinical trial and has the potential to transform vaccines against HIV and malaria.

Newswise: Researchers Find That a Japanese Medicinal Mushroom Extract Can Help the Body Clear Persistent HPV Infections
Released: 22-Jun-2022 8:30 AM EDT
Researchers Find That a Japanese Medicinal Mushroom Extract Can Help the Body Clear Persistent HPV Infections
AHCC Research Association

According to a paper published in Frontiers in Oncology, daily use of a unique mushroom extract AHCC® supported the immune system in clearing HPV infections in two-thirds of study participants after six months of supplementation.

21-Jun-2022 5:05 PM EDT
New Treatment Option Shows Promise in Clearing HPV Infection
University of Texas Health Science Center at Houston

Daily use of a mushroom extract supported the immune system in clearing human papillomavirus (HPV) infections, according to researchers with UTHealth Houston. The study was published today in Frontiers in Oncology.

Newswise: JNCCN: Mismatch in Breast Cancer Trial Results and Real-World Outcomes Based on Treatment Discontinuation
Released: 21-Jun-2022 8:30 AM EDT
JNCCN: Mismatch in Breast Cancer Trial Results and Real-World Outcomes Based on Treatment Discontinuation
National Comprehensive Cancer Network® (NCCN®)

New population study in JNCCN on adjuvant hormone therapy for breast cancer finds correlation between hot flashes and poorer outcomes—in contrast to clinical trial results; likely due to patients with side-effects ending treatment early.

Newswise: MD Anderson, Invectys and CTMC announce strategic collaboration for CAR T cell therapy development
Released: 16-Jun-2022 8:00 AM EDT
MD Anderson, Invectys and CTMC announce strategic collaboration for CAR T cell therapy development
University of Texas M. D. Anderson Cancer Center

MD Anderson, Invectys and CTMC announced a strategic collaboration to develop CAR T cell therapies targeting HLA-G for treating solid tumors.

Newswise: Varenicline Increases Smoking Cessation Rates for African American Smokers
Released: 14-Jun-2022 1:05 PM EDT
Varenicline Increases Smoking Cessation Rates for African American Smokers
University of Kansas Cancer Center

Researchers at The University of Kansas Cancer Center have released the results of a clinical trial that examined the effectiveness of varenicline in African Americans. In their study published in JAMA, African American daily smokers who were given varenicline while receiving counseling had significantly greater quit rates than those who received a placebo.

Released: 13-Jun-2022 8:00 AM EDT
Study Finds No Benefit to Taking Ivermectin for COVID-19 Symptoms
Duke Clinical Research Institute

A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no differences in relief of mild-to-moderate COVID-19 symptoms between participants taking ivermectin and participants taking a placebo.

Released: 12-Jun-2022 10:05 PM EDT
NUS AI Platform Enables Doctors to Optimise Personalised Chemotherapy Dose
National University of Singapore

A team of researchers from National University of Singapore, in collaboration with clinicians from the National University Cancer Institute, Singapore which is part of the National University Health System, has reported promising results in using CURATE.AI, an artificial intelligence tool that identifies and better allows clinicians to make optimal and personalised doses of chemotherapy for patients.

Newswise: Study of Anti-Cancer Mitochondrial Drug Shows Additional Clinical Promise
Released: 9-Jun-2022 12:05 PM EDT
Study of Anti-Cancer Mitochondrial Drug Shows Additional Clinical Promise
Stony Brook University

A study of the lead agent (CPI-613) in a class of anticancer drugs undergoing Food and Drug Administration (FDA) approved clinical trials reveals that CPI-613 is effective against most carcinoma cell lines, and, used in combination, could have efficacy against reducing some tumors.

6-Jun-2022 9:00 AM EDT
Analysis Finds Little Evidence of Heart Problems in Men Undergoing Testosterone Treatment
Endocrine Society

Previous clinical trials have provided insufficient evidence to decide whether testosterone causes heart problems in men during the first year of treatment, according to research being presented Monday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga., and published in The Lancet Healthy Longevity.

Newswise:Video Embedded gene-therapy-for-rare-eye-disease-safe-but-lacks-efficacy-in-early-trial
VIDEO
Released: 7-Jun-2022 5:05 PM EDT
Gene Therapy for Rare Eye Disease Safe but Lacks Efficacy in Early Trial
NIH, National Eye Institute (NEI)

Byron Lam and collaborators at the University of Miami reported results from an 8-patient phase 1 gene therapy clinical trial for the degenerative retinal disease Leber hereditary optic neuropathy. They found no significant safety concerns; however, treatment failed to improve or slow vision loss, with even the highest dose.

Newswise: Roswell Park-Developed Immunotherapy Now Part of Nationwide Study in Kids With Brain Cancer
Released: 7-Jun-2022 2:05 PM EDT
Roswell Park-Developed Immunotherapy Now Part of Nationwide Study in Kids With Brain Cancer
Roswell Park Comprehensive Cancer Center

The immunotherapy SurVaxM is being utilized in a pilot study in children and adolescents with several brain cancer types through a multicenter trial sponsored by the Pediatric Brain Tumor Consortium (PBTC).

Released: 7-Jun-2022 11:00 AM EDT
From ASCO 2022: Brentuximab Vedotin and Chemotherapy an Effective Treatment for Hodgkin Lymphoma
Roswell Park Comprehensive Cancer Center

New research led by Kara Kelly, MD, of Roswell Park Comprehensive Cancer Center and presented today at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago shows that a combination of brentuximab vedotin (Bv) and standard chemotherapy is safe and more effective than standard chemotherapy in pediatric patients up to age 21 years with newly diagnosed high-risk Hodgkin lymphoma. The findings from a phase 3 National Cancer Institute-supported multicenter Children’s Oncology Group clinical trial (NCT 02166463) were presented by first author Sharon Castellino, MD, of Emory University and Children’s Healthcare of Atlanta in an oral abstract session on Friday, June 3.

Released: 7-Jun-2022 10:45 AM EDT
MD Anderson Researchers Present Encouraging Results of Early-Stage Clinical Trials at 2022 ASCO Annual Meeting
University of Texas M. D. Anderson Cancer Center

Results from three early-stage clinical trials led by researchers at The University of Texas MD Anderson Cancer Center show promising activity with novel immunotherapies and targeted therapies for patients with advanced tumors.

Released: 7-Jun-2022 8:05 AM EDT
Evolution Research Group, LLC Acquires Ohio Clinical Trials, LLC Further Expanding Clinical Pharmacology & Early Stage Development Service Capabilities
Evolution Research Group, LLC

Evolution Research Group, LLC (ERG), a privately held, independent pharmaceutical services provider focused on neuroscience announced the acquisition of Ohio Clinical Trials (OCT), a 64-bed phase 1 unit in Columbus, OH, that specializes in the execution of human abuse potential (HAP) studies, as well as other highly complex early phase trials including pain modeling, qEEG/EEG, respiratory depression, and alcohol interaction, among others.

Newswise: Cedars-Sinai Cancer Experts Available to Comment on AACR Cancer Disparities Progress Report
Released: 6-Jun-2022 4:05 PM EDT
Cedars-Sinai Cancer Experts Available to Comment on AACR Cancer Disparities Progress Report
Cedars-Sinai

Experts from Cedars-Sinai Cancer are available to comment on the American Association for Cancer Research (AACR) Cancer Disparities Progress Report 2022, which will be released Wednesday, June 8, in a virtual congressional briefing. The report highlights the need to increase diversity in clinical trials and the cancer workforce, and it provides policy recommendations for addressing cancer disparities—all areas Cedars-Sinai Cancer is working to address.

Newswise: Roswell Park Expert to Present on Effectiveness of New Combination for Acute Myeloid Leukemia
Released: 6-Jun-2022 11:05 AM EDT
Roswell Park Expert to Present on Effectiveness of New Combination for Acute Myeloid Leukemia
Roswell Park Comprehensive Cancer Center

On Tuesday, June 7, Eunice Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, will present the long-term results of a phase 2 clinical trial combining crenolanib, a second-generation FLT3 inhibitor, with standard intensive chemotherapy for treatment of adults with newly diagnosed FLT3-mutant acute myeloid leukemia (AML), in a talk at the American Society of Clinical Oncology (ASCO) annual meeting 2022.

Released: 5-Jun-2022 12:05 PM EDT
Improved Progression-Free Survival in Multiple Myeloma Patients Following Three-Drug Therapy with Autologous Stem Cell Transplant
Dana-Farber Cancer Institute

Patients with multiple myeloma who have been treated with a three-drug combination therapy have a growing number of choices for subsequent treatment. Results of a new study led by researchers at Dana-Farber Cancer Institute can help patients and their physicians weigh benefits and risks of each option.

Released: 4-Jun-2022 8:00 AM EDT
Immunotherapy Before Surgery Associated with Improved Survival for Soft-Tissue Sarcoma
University of Texas M. D. Anderson Cancer Center

In a Phase II clinical trial, immune checkpoint blockade before surgery was associated with favorable responses and outcomes in undifferentiated pleomorphic sarcoma (UPS) and recurrent dedifferentiated liposarcoma (DDLPS), researchers from The University of Texas MD Anderson Cancer Center reported today at the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting.

Released: 3-Jun-2022 5:30 PM EDT
Promising Results for Chemo-Immunotherapy Combination Against Pancreatic Cancer, Penn Study Finds
Perelman School of Medicine at the University of Pennsylvania

A combination of chemotherapy with an immunotherapy meant to unleash the anticancer capacity of the immune system was effective against one of the hardest targets in cancer care, pancreatic cancer, in a national, randomized clinical trial led by researchers at the Perelman School of Medicine at the University of Pennsylvania, and sponsored by the Parker Institute for Cancer Immunotherapy.

Newswise: ASCO22: Lung Cancer Therapy Could Help Patients Live Longer
Released: 3-Jun-2022 4:05 PM EDT
ASCO22: Lung Cancer Therapy Could Help Patients Live Longer
Cedars-Sinai

Results of a Phase II clinical trial led by Cedars-Sinai Cancer investigators indicate that an immunotherapy drug combination could extend the lives of those diagnosed with advanced non-small cell lung cancer, one of the most common forms of lung cancer. The research was presented today during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, with simultaneous publication in the peer-reviewed Journal of Clinical Oncology.

Newswise: Pediatric Lymphoma Trial and Study of FLT3 Inhibitor for Leukemia Highlight Roswell Park Research at ASCO22
Released: 1-Jun-2022 4:30 PM EDT
Pediatric Lymphoma Trial and Study of FLT3 Inhibitor for Leukemia Highlight Roswell Park Research at ASCO22
Roswell Park Comprehensive Cancer Center

Researchers from Roswell Park Comprehensive Cancer Center will present the latest results of clinical trials and insights on cancer treatment and issues affecting patients with cancer, including the financial burdens induced by cancer treatment, at the annual meeting of the American Society of Clinical Oncology (ASCO), which will take place both online and in-person in Chicago, Illinois, from June 3 to 7.

Newswise: University of Miami Miller School of Medicine Selected for National NF2 Tumor Clinical Trial
Released: 1-Jun-2022 12:05 PM EDT
University of Miami Miller School of Medicine Selected for National NF2 Tumor Clinical Trial
University of Miami Health System, Miller School of Medicine

A University of Miami Miller School of Medicine researcher is hoping an innovative multicenter clinical trial will lead to new therapies for neurofibromatosis type 2 (NF2), a devastating disease causing multiple types of tumors involving the brain, spine, and peripheral nerves.

Newswise: Decoding How a Protein on the Move Keeps Cells Healthy
Released: 31-May-2022 6:05 PM EDT
Decoding How a Protein on the Move Keeps Cells Healthy
Cold Spring Harbor Laboratory

Cells produce proteins like little factories. But if they make too much at the wrong times it can lead to diseases like cancer, so they control production with a process called RNA interference (RNAi).

Newswise: Investigational Drug Attacks Synovial Sarcoma, a Rare Type of Tumor
Released: 31-May-2022 4:05 PM EDT
Investigational Drug Attacks Synovial Sarcoma, a Rare Type of Tumor
Washington University in St. Louis

Researchers at Washington University School of Medicine in St. Louis have developed a way to attack synovial sarcoma — a rare tumor of soft tissues, such as ligaments and muscles — using an investigational drug that triggers cell death.

Released: 26-May-2022 2:05 PM EDT
Investigational Drug Trial Seeks Male Volunteers with Chronic Kidney Diseases
Saint Louis University Medical Center

Researchers at Saint Louis University School of Medicine are enrolling volunteers in an investigational drug trial for hypogonadal men with chronic kidney disease.

Newswise: Annual Report Highlights From Cedars-Sinai Cancer
Released: 25-May-2022 5:05 PM EDT
Annual Report Highlights From Cedars-Sinai Cancer
Cedars-Sinai

The 2022 Annual Report from Cedars-Sinai Cancer, which is available now, shines a spotlight on ways this expert team, ranked among the top 10 in the nation for cancer care by U.S. News & World Report, has treated more than 60 types of cancer while honoring and expanding a long-standing commitment to health equity.

Released: 24-May-2022 12:40 PM EDT
Medicare Program Spent $1.8 Billion in 2019 on Drugs Without Confirmed Clinical Benefits
Johns Hopkins Bloomberg School of Public Health

Study found that some drugs were on the market for over five years with no confirmed clinical benefit.

Newswise: Expert available to comment on improving representation in clinical trials and research
Released: 24-May-2022 12:00 PM EDT
Expert available to comment on improving representation in clinical trials and research
Indiana University

Indiana University's Amy Knopf can speak about the impacts of a recent National Academies of Sciences, Engineering, and Medicine report, "Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups."

Released: 24-May-2022 11:00 AM EDT
Susan G. Komen Awards Grant to Define and Advance Diagnosis of Inflammatory Breast Cancer
Susan G. Komen

Susan G. Komen awarded a research grant to apply a new, first-of-its-kind tool that seeks to more accurately diagnose inflammatory breast cancer (IBC).

Released: 23-May-2022 9:00 AM EDT
V-Wave's Ventura® Interatrial Shunt: One Year Follow-up from RELIEVE-HF Roll-in Arm Shows Improved Left and Right Ventricular Function in Patients with Advanced Heart Failure
V-Wave Ltd.

V-Wave Ltd, manufacturer of the V-Wave Ventura investigational interatrial shunt device to help patients with advanced heart failure (HF), announced 12-month echocardiographic results from the open label Roll-in arm of the RELIEVE-HF pivotal clinical trial, comprising 97 NYHA Class III or ambulatory Class IV HF patients who were already on maximally tolerated guideline directed medical therapy.

Released: 19-May-2022 2:50 PM EDT
Study tests link between common blood pressure pills and breast cancer
Curtin University

Curtin University researchers will examine if the long-term use of a popular blood pressure medication increased the risk of breast cancer in almost 200,000 women as part of a new project supported by the Federal Government.

Newswise: Imatinib Shows Improved Outcomes for Patients with Severe COVID-19 in the CounterCOVID Clinical Trial
9-May-2022 4:00 PM EDT
Imatinib Shows Improved Outcomes for Patients with Severe COVID-19 in the CounterCOVID Clinical Trial
American Thoracic Society (ATS)

Patients with severe COVID-19 who were given imatinib had lower mortality rates at 90-day follow-up, according to research published at the ATS 2022 international conference.

Newswise: New Weight-Loss Intervention Targets Instinctive Desire to Eat
17-May-2022 1:35 PM EDT
New Weight-Loss Intervention Targets Instinctive Desire to Eat
University of California San Diego

People who are highly responsive to food lost more weight and kept it off using a new weight loss program that targets internal hunger cues and the ability to resist food, reports University of California San Diego Herbert Wertheim School of Public Health and Human Longevity Science.

Newswise: After Sprint for COVID-19 Vaccines, HVTN Researchers Return to HIV Marathon With Fresh Determination and Knowledge, Launch Clinical Research Registry and Ad Campaign
Released: 18-May-2022 9:55 AM EDT
After Sprint for COVID-19 Vaccines, HVTN Researchers Return to HIV Marathon With Fresh Determination and Knowledge, Launch Clinical Research Registry and Ad Campaign
HIV Vaccine Trials Network

SEATTLE (May 18, 2022) – Building on momentum from the highly successful COVID-19 vaccine clinical trials, the HIV Vaccine Trials Network (HVTN) is launching a new HIV awareness campaign and unveiling a first-of-its-kind national registry that will provide updated HIV information and make it easier to learn about and participate in HIV clinical trials at HelpEndHIV.org.

Released: 17-May-2022 9:05 AM EDT
Pulmonary Fibrosis Foundation Expands Clinical Trial Resources for Patients
Pulmonary Fibrosis Foundation

The Pulmonary Fibrosis Foundation (PFF) has developed new materials and tools for people living with pulmonary fibrosis (PF) to learn about and enroll in clinical research studies.

Released: 15-May-2022 2:05 PM EDT
Researchers Find Favorable Tradeoffs of PSA Screening for Prostate Cancer
University Hospitals Cleveland Medical Center

University Hospitals’ Jonathan Shoag, MD, and a team of researchers from Case Western Reserve University and the Case Comprehensive Cancer Center, Weill Cornell Medical Center, the Fred Hutchinson Cancer Research Center, and others, set out to assess the tradeoffs of PSA screening using long-term epidemiologic data. “No matter the assumptions,” Shoag said, “the data showed lower numbers than prior estimates, many in the low single digits, for the number needed to treat to prevent a prostate-cancer death. This result was observed in all men, and especially for Black men.” The researchers presented their findings in a late-breaking abstract at the American Urological Association’s annual meeting this month and the study was published May 15 in The New England Journal of Medicine Evidence.

Newswise: Early Study Finds New Lymphoma Drug Effective
Released: 13-May-2022 10:50 AM EDT
Early Study Finds New Lymphoma Drug Effective
Michigan Medicine - University of Michigan

In early research led by the University of Michigan Health Rogel Cancer Center, the oral medication zanubrutinib was found to help most patients with a slow-growing type of cancer known as marginal zone lymphoma.

Released: 13-May-2022 2:00 AM EDT
Multimodal Chronic Pain Therapy for Adults via Smartphone: Randomized Controlled Clinical Trial
Journal of Medical Internet Research

Background: Combination therapies delivered remotely via the internet or mobile devices are increasingly being used to improve and promote the self-management of chronic conditions. However, little is known regarding the long-term ef...

Newswise: Fast-tracked: First in-human trial for aggressive brain tumours
Released: 12-May-2022 12:05 AM EDT
Fast-tracked: First in-human trial for aggressive brain tumours
University of South Australia

A novel technology designed to precisely image aggressive brain cancers and guide treatment is being developed by the University of South Australia and Australian cancer diagnostic company, Ferronova, potentially helping thousands of people who are diagnosed with the deadly condition each year.

Released: 11-May-2022 8:00 AM EDT
First Patients Dosed in Phase 2 Platform Clinical Trial Testing Novel Immunotherapy Combinations in Highly Malignant Ovarian Cancer
Cancer Research Institute (CRI) and Ovarian Cancer Research Alliance (OCRA)

A phase 2 clinical trial testing novel immunotherapy combinations in aggressive ovarian cancer has opened and first patients have begun treatment.


Showing results

150 of 1335

close
1.84887